Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non–Small Cell Lung Cancer

Sepesi, Boris; Cascone, Tina; Chun, Stephen G.; Altan, Mehmet; Le, Xiuning

doi:10.1016/j.soc.2020.06.009

Cited by 9 publications

(5 citation statements)

References 97 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In view of the lack of significant early symptoms of lung cancer, patients are often in an advanced stage [ 6 ]. In recent years, the targeted therapy of lung cancer has made important progress, and a variety of targeted drugs emerge in endlessly [ 7 , 8 ]. In order to further improve the prognosis of patients, it is still necessary to identify more potential therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1

Luo

Zhuo

et al. 2021

BMC Pulm Med

View full text Add to dashboard Cite

Background To detect and investigate the expression of POU domain class 2 transcription factor 2 (POU2F2) in human lung cancer tissues, its role in lung cancer progression, and the potential mechanisms. Methods Immunohistochemical (IHC) assays were conducted to assess the expression of POU2F2 in human lung cancer tissues. Immunoblot assays were performed to assess the expression levels of POU2F2 in human lung cancer tissues and cell lines. CCK-8, colony formation, and transwell-migration/invasion assays were conducted to detect the effects of POU2F2 and AGO1 on the proliferaion and motility of A549 and H1299 cells in vitro. CHIP and luciferase assays were performed for the mechanism study. A tumor xenotransplantation model was used to detect the effects of POU2F2 on tumor growth in vivo. Results We found POU2F2 was highly expressed in human lung cancer tissues and cell lines, and associated with the lung cancer patients’ prognosis and clinical features. POU2F2 promoted the proliferation, and motility of lung cancer cells via targeting AGO1 in vitro. Additionally, POU2F2 promoted tumor growth of lung cancer cells via AGO1 in vivo. Conclusion We found POU2F2 was highly expressed in lung cancer cells and confirmed the involvement of POU2F2 in lung cancer progression, and thought POU2F2 could act as a potential therapeutic target for lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1

Luo

Zhuo

et al. 2021

BMC Pulm Med

View full text Add to dashboard Cite

show abstract

“…To overcome this issue, the artificially designed high-affinity TCR is encoded in T cells by genetic engineering. The basic principle of TCR-T-cell therapy is to modify the patient's own T cells ex vivo to express tumor antigen-specific TCRs and then expand and reinject them back into the patient's body to specifically attack malignant tissue (155). The host antitumor immune response selects and activates T cells that recognize tumor antigens.…”

Section: T-cell Receptor-t Cellmentioning

confidence: 99%

T lymphocyte cell: A pivotal player in lung cancer

Yuan

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Lung cancer is responsible for the leading cause of cancer-related death worldwide, which lacks effective therapies. In recent years, accumulating evidence on the understanding of the antitumor activity of the immune system has demonstrated that immunotherapy is one of the powerful alternatives in lung cancer therapy. T cells are the core of cellular immunotherapy, which are critical for tumorigenesis and the treatment of lung cancer. Based on the different expressions of surface molecules and functional points, T cells can be subdivided into regulatory T cells, T helper cells, cytotoxic T lymphocytes, and other unconventional T cells, including γδ T cells, nature killer T cells and mucosal-associated invariant T cells. Advances in our understanding of T cells’ functional mechanism will lead to a number of clinical trials on the discovery and development of new treatment strategies. Thus, we summarize the biological functions and regulations of T cells on tumorigenesis, progression, metastasis, and prognosis in lung cancer. Furthermore, we discuss the current advancements of technologies and potentials of T-cell-oriented therapeutic targets for lung cancer.

show abstract

“…Western medicine approaches immunotherapy with careful consideration of each patient’s variability and sensitivity to these toxicities. Tailored dosing is often necessary to optimize the benefits while minimizing adverse effects ( 70 ).…”

Section: Treatment Of Lung Adenocarcinoma With the Combination Of Tra...mentioning

confidence: 99%

Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine

Jiang,

2024

Front. Med.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) overwhelmingly represents the predominant histological subtype of lung cancer, with lung adenocarcinoma emerging as the most prevalent form. Conventional Western medical treatments encompass a spectrum of modalities, including surgical interventions, cytotoxic chemotherapy, radiotherapy, targeted pharmacotherapy, and immunotherapy. In contrast, Traditional Chinese Medicine (TCM) methodologies encompass traditional Chinese medicine treatments, acupuncture therapies, and tuina treatments. While conventional Western medicine has made remarkable strides in the treatment of lung cancer, it is important to acknowledge the limitations inherent in singular treatment approaches. Consequently, the quest for a more comprehensive and integrative therapeutic paradigm becomes imperative. A deficiency of evaluation criteria specific to lung adenocarcinoma treatment in the realm of TCM represents an outstanding challenge in need of resolution. Nonetheless, in the backdrop of the continuous evolution of lung adenocarcinoma treatment modalities, the amalgamation of Chinese and Western medical approaches for treating this condition has exhibited a promising trajectory. It not only contributes to mitigating toxicity and augmenting efficacy but also serves to reduce a spectrum of postoperative complications, thereby enhancing the quality of patients’ survival and extending life expectancy. This article furnishes a comprehensive survey of the research advancements in the integration of Chinese and Western medical approaches for treating lung adenocarcinoma. It elucidates the merits and demerits of individual and combined therapeutic strategies, surmounts current limitations, underscores the virtues of amalgamating Chinese and Western medical paradigms, and offers a more holistic, integrated, and efficacious treatment blueprint.

show abstract

Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non–Small Cell Lung Cancer

Cited by 9 publications

References 97 publications

POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1

POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1

T lymphocyte cell: A pivotal player in lung cancer

Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine

Contact Info

Product

Resources

About